4 transcripts
REGN
Earnings call transcript
NASDAQ
2024 Q2
1 Aug 24
longer-term follow-up on the metastatic melanoma cohorts from our first-in-human study. Responses have continued to deepen with the proportion
REGN
Earnings call transcript
NASDAQ
2024 Q1
2 May 24
comparisons caveat supply, we believe linvoseltamab represents a best-in-class opportunity because it has the highest objective response rates and complete
REGN
Earnings call transcript
NASDAQ
2023 Q4
2 Feb 24
the complete response letter in late June due to an issue at a third-party filler. But this was quickly remedied and EYLEA HD was granted approval in mid-August
REGN
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
Response Letter, or CRL, that we received from the FDA regarding our biologic license application for aflibercept 8 milligrams for the treatment
- Prev
- 1
- Next